Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · see citing works

A small molecule–kinase interaction map for clinical kinase inhibitors

Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,901 · see citing works

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356 · see citing works

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338 · see citing works

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · see citing works

Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle

Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,169 · see citing works

D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA

Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021 · see citing works

Targeted protein degradation: expanding the toolbox

Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · see citing works

Specific protection against breast cancers by cyclin D1 ablation

Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · see citing works

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852 · see citing works

Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

Fantl, V, Stamp, G., Andrews, A., Rosewell, I., & Dickson, C. (1995) · Genes & Development · doi:10.1101/gad.9.19.2364 · Cited by 691 · see citing works

Human D-type cyclin

Xiong, Y., Connolly, T., Futcher, B., & Beach, D. (1991) · Cell · doi:10.1016/0092-8674(91)90100-d · Cited by 687 · see citing works

Advancing targeted protein degradation for cancer therapy

Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 671 · see citing works

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652 · see citing works

Targeted protein degradation by PROTACs

Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599 · see citing works

Targeting RNA structures with small molecules

Childs‐Disney, J. L., Yang, X., Gibaut, Q. M. R., Tong, Y., Batey, R., & Disney, M. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00521-4 · Cited by 599 · see citing works

Cyclins and cyclin-dependent kinases: a biochemical view

Pines, J. (1995) · Biochemical Journal · doi:10.1042/bj3080697 · Cited by 538 · see citing works

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513 · see citing works

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444 · see citing works

Selective Inhibitors of the Proteasome-dependent and Vacuolar Pathways of Protein Degradation in Saccharomyces cerevisiae

Lee, D. H., & Goldberg, A. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27280 · Cited by 408 · see citing works

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

Álvarez‐Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 395 · see citing works

The Requirement for Cyclin D Function in Tumor Maintenance

Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342 · see citing works

The PROTACtable genome

Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273 · see citing works

Development of dual and selective degraders of cyclin-dependent kinases 4 and 6

Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272 · see citing works

An H3K36 Methylation-Engaging Tudor Motif of Polycomb-like Proteins Mediates PRC2 Complex Targeting

Cai, L., Rothbart, S. B., Lu, R., Xu, B., Chen, W., Tripathy, A., Rockowitz, S., Zheng, D., Patel, D. J., Allis, C. D., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.11.026 · Cited by 253 · see citing works

TF-PROTACs Enable Targeted Degradation of Transcription Factors

Liu, J., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03852 · Cited by 247 · see citing works

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

Guiley, K. Z., Stevenson, J. W., Lou, K., Barkovich, K. J., Kumarasamy, V. M., Wijeratne, T. U., Bunch, K. L., Tripathi, S. M., Knudsen, E. S., Witkiewicz, A. K., et al. (2019) · Science · doi:10.1126/science.aaw2106 · Cited by 225 · see citing works

Small Molecule Targeted Recruitment of a Nuclease to RNA

Costales, M. G., Matsumoto, Y., Velagapudi, S. P., & Disney, M. D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01233 · Cited by 212 · see citing works

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders

Su, S., Yang, Z., Gao, H., Yang, H., Zhu, S., An, Z., Wang, J., Li, Q., Chandarlapaty, S., Deng, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00871 · Cited by 209 · see citing works

Differential Regulation of Retinoblastoma Tumor Suppressor Protein by G 1 Cyclin-Dependent Kinase Complexes In Vivo

Ezhevsky, S. A., Ho, A. L., Becker‐Hapak, M., Davis, P. K., & Dowdy, S. F. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4773-4784.2001 · Cited by 208 · see citing works

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Hsu, J. H.-R., Rasmusson, T., Robinson, J., Pachl, F., Read, J., Kawatkar, S., O’ Donovan, D. H., Bagal, S., Code, E., Rawlins, P., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.004 · Cited by 202 · see citing works

Targeting RNA with Small Molecules To Capture Opportunities at the Intersection of Chemistry, Biology, and Medicine

Disney, M. D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13419 · Cited by 200 · see citing works

RNA‐PROTACs: Degraders of RNA‐Binding Proteins

Ghidini, A., Cléry, A., Halloy, F., Allain, F. H. T., & Hall, J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202012330 · Cited by 197 · see citing works

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

Wang, J., Yu, X., Gong, W., Liu, X., Park, K., Ma, A., Tsai, Y., Shen, Y., Onikubo, T., Pi, W., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00850-x · Cited by 187 · see citing works

Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras

Samarasinghe, K. T. G., Jaime-Figueroa, S., Burgess, M., Nalawansha, D. A., Dai, K., Hu, Z., Bebenek, A., Holley, S. A., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.011 · Cited by 182 · see citing works

Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader

Potjewyd, F., Turner, A. W., Beri, J., Rectenwald, J. M., Norris-Drouin, J. L., Cholensky, S. H., Margolis, D. M., Pearce, K. H., Herring, L. E., & James, L. I. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.006 · Cited by 179 · see citing works

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Wei, J., Meng, F., Park, K.-S., Yim, H., Velez, J., Kumar, P., Wang, L., Xie, L., Chen, H., Shen, Y., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c04841 · Cited by 154 · see citing works

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models

Yu, X., Li, D., Kottur, J., Shen, Y., Kim, H. S., Park, K., Tsai, Y., Gong, W., Wang, J., Suzuki, K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj1578 · Cited by 154 · see citing works

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2

Liu, Z., Hu, X., Wang, Q., Wu, X., Zhang, Q., Wei, W., Su, X., He, H., Zhou, S., Hu, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02234 · Cited by 125 · see citing works

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Shao, J., Yan, Y., Ding, D., Wang, D., He, Y., Pan, Y., Yan, W., Kharbanda, A., Li, H., & Huang, H. (2021) · Advanced Science · doi:10.1002/advs.202102555 · Cited by 120 · see citing works

Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders

Shen, Y., Gao, G., Yu, X., Kim, H., Wang, L., Xie, L., Schwarz, M. C., Chen, X., Guccione, E., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01111 · Cited by 107 · see citing works

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr02 · Cited by 106 · see citing works

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma

Tu, Y., Sun, Y., Qiao, S., Luo, Y., Liu, P., Jiang, Z., Hu, Y., Wang, Z., Huang, P., & Wen, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00460 · Cited by 101 · see citing works

Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer

Li, J., Liu, T., Song, Y., Wang, M., Liu, L., Zhu, H., Li, Q., Lin, J. H., Jiang, H., Chen, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00257 · Cited by 89 · see citing works

Drugging “undruggable” genes for cancer treatment: Are we making progress?

Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 85 · see citing works

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders

Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00174-z · Cited by 74 · see citing works

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2

Dale, B., Anderson, C., Park, K., Kanıskan, H. Ü., Ma, A., Shen, Y., Zhang, C., Xie, L., Chen, X., Yu, X., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00100 · Cited by 66 · see citing works

Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands

Naganuma, M., Ohoka, N., Tsuji, G., Tsujimura, H., Matsuno, K., Inoué, T., Naito, M., & Demizu, Y. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00629 · Cited by 30 · see citing works

RNA‐PROTACs: Degraders of RNA‐Binding Proteins

Ghidini, A., Cléry, A., Halloy, F., Allain, F. H. ‐., & Hall, J. (2020) · Angewandte Chemie · doi:10.1002/ange.202012330 · Cited by 20 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02024-9 · Cited by 192 · see citing works

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity

Chen, C., Yang, Y., Wang, Z., Li, H., Dong, C., & Zhang, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00302 · Cited by 117 · see citing works

Annual review of PROTAC degraders as anticancer agents in 2022

Wang, X., Qin, Z.-L., Li, N., Jia, M.-Q., Liu, Q.-G., Bai, Y., Song, J., Yuan, S., & Zhang, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116166 · Cited by 107 · see citing works

Targeting the undruggables—the power of protein degraders

Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 108 · see citing works

Discovery of a PROTAC degrader for METTL3-METTL14 complex

Du, W., Huang, Y., Chen, X., Deng, Y. W., Sun, Y., Yang, H., Shi, Q., Wu, F., Liu, G., Huang, H., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2023.12.009 · Cited by 78 · see citing works

Antiviral PROTACs: Opportunity borne with challenge

Liang, J., Wu, Y., Lan, K., Dong, C., Wu, S., Li, S., & Zhou, H. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100092 · Cited by 74 · see citing works

PROTACs: A novel strategy for cancer drug discovery and development

Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 67 · see citing works

Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy

Peng, Y., Liu, J., Inuzuka, H., & Wei, W. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104572 · Cited by 66 · see citing works

Acetylation targeting chimera enables acetylation of the tumor suppressor p53

Kabir, M., Sun, N., Hu, X., Martin, T. C., Yi, J., Zhong, Y., Xiong, Y., Kaniskan, H. Ü., Gu, W., Parsons, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04640 · Cited by 65 · see citing works

Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates

Huang, H., Lumpkin, R. J., Tsai, R. W., Su, S., Zhao, X., Xiong, Y., Chen, J., Mageed, N., Donovan, K. A., Fischer, E. S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01590-9 · Cited by 64 · see citing works

Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer

Asciolla, J. J., Wu, X., Adamopoulos, C., Gavathiotis, E., & Poulikakos, P. I. (2025) · Nature Cancer · doi:10.1038/s43018-024-00893-z · Cited by 62 · see citing works

Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design

Chen, Y., Liu, F., Pal, S., & Hu, Q. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00411f · Cited by 55 · see citing works

A PROTAC‐Based Cuproptosis Sensitizer in Lung Cancer Therapy

Wang, Y., Yao, X., Lu, Y., Ruan, J., Yang, Z., Wang, C., Yang, N., Gao, Y., & Shi, S. (2025) · Advanced Materials · doi:10.1002/adma.202501435 · Cited by 56 · see citing works

Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc Protein

Wang, Y., Yang, G., Zhang, X., Bai, R., Yuan, D., Gao, D., He, Q., Yuan, Y., Zhang, X., Kou, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202309639 · Cited by 51 · see citing works

Overcoming cancer therapy resistance: From drug innovation to therapeutics

Wei, J., Lu, M., Wei, T., Fleishman, J. S., Yu, H. J., Chen, X.-L., Kong, X.-T., Sun, S., Li, N., Yang, Y., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101229 · Cited by 50 · see citing works

Development of PROTAC degrader probe of CDK4/6 based on DCAF16

Pu, C., Liu, Y., Deng, R., Xu, Q., Wang, S., Zhang, H., Luo, D., Ma, X., Tong, Y., Ma, X., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106637 · Cited by 43 · see citing works

Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex

Wang, M., Lin, R., Li, J., Suo, Y., Gao, J., Liu, L., Zhou, L., Ni, Y., Yang, Z., Zheng, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02045 · Cited by 42 · see citing works

Strategies for Precise Modulation of Protein Degradation

He, S., Dong, G., & Sheng, C. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00003 · Cited by 41 · see citing works

Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions

Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 44 · see citing works

Mitochondrial Protease Targeting Chimeras for Mitochondrial Matrix Protein Degradation

Wang, D., Wang, W., Fang, L., Qi, L., Zhang, Y., Liu, J., Liang, Y., Yang, H., Wang, M., Wei, X., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03756 · Cited by 38 · see citing works

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Guo, Y., Li, Y., Zhou, Z., Hou, L., Liu, W., Ren, W., Mi, D., Sun, J., Dai, X., Wu, Y., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03237-y · Cited by 37 · see citing works

Dual‐Programmable Semiconducting Polymer NanoPROTACs for Deep‐Tissue Sonodynamic‐Ferroptosis Activatable Immunotherapy

Wang, F., Dong, G., Ding, M., Yu, N., Sheng, C., & Li, J. (2023) · Small · doi:10.1002/smll.202306378 · Cited by 36 · see citing works

PROTACs Targeting MLKL Protect Cells from Necroptosis

Rathje, O. H., Perryman, L., Payne, R. J., & Hamprecht, D. W. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00665 · Cited by 35 · see citing works

Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020–2024)

Cheng, B., Lv, J., Xiao, Y., Song, C., Chen, J., & Shao, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117141 · Cited by 35 · see citing works

Chemically induced degradation of epigenetic targets

Kabir, M., Yu, X., Kanıskan, H. Ü., & Jin, J. J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00100h · Cited by 35 · see citing works

Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders

Tang, J., Moorthy, R., Hirsch, L. E., Demir, Ö., Baker, Z. D., Naumann, J. A., Jones, K. F. M., Grillo, M. J., Haefner, E. S., Shi, K., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2024.12.006 · Cited by 33 · see citing works

Recent Progress in CDK4/6 Inhibitors and PROTACs

Wang, H., Ba, J., Kang, Y., Gong, Z., Liang, T., Zhang, Y., Qi, J., & Wang, J. (2023) · Molecules · doi:10.3390/molecules28248060 · Cited by 32 · see citing works

Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma

Fu, X., Huang, J., Chen, X., Xie, D., Chen, H., Liang, Z., Wang, Z., Liang, Y., Lü, A., & Liang, C. (2024) · Theranostics · doi:10.7150/thno.99588 · Cited by 30 · see citing works

p53 in colorectal cancer: from a master player to a privileged therapy target

Yan, S., Zhan, F., He, Y., Zhu, Y., & Ma, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06566-4 · Cited by 33 · see citing works

Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues

Marei, H. E. S., Bedair, K., Hasan, A., Al-Mansoori, L., Gaiba, A., Morrione, A., Cenciarelli, C., & Giordano, A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00931-8 · Cited by 30 · see citing works

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

Cheng, B., Fei, X., Ding, Z., Peng, X., Su, Z., Pan, W., & Chen, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00015 · Cited by 27 · see citing works

Amphiphilic Affibody-PROTAC conjugate Self-Assembled nanoagents for targeted cancer therapy

Gao, W., Xia, X., Yang, X., Li, Q., Xia, X., Huang, W., & Yan, D. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.153437 · Cited by 25 · see citing works

Recent advances in developing targeted protein degraders

Cheng, B., Li, H., Peng, X., Chen, J., Shao, C., & Kong, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117212 · Cited by 25 · see citing works

Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons

Ibrahim, S., Khan, M. U., Khurram, I., Rehman, R., Rauf, A., Ahmad, Z., Aljohani, A. S. M., Abdulmonem, W. A., & Quradha, M. M. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70011 · Cited by 23 · see citing works

Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning

Tan, S., Chen, Z., Lu, R., Liu, H., & Yao, X. (2025) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70013 · Cited by 23 · see citing works

The Peptide PROTAC Modality: A New Strategy for Drug Discovery

Zhu, Y., Dai, Y., & Tian, Y. (2025) · MedComm · doi:10.1002/mco2.70133 · Cited by 23 · see citing works

Discovery of the First-in-Class G9a/GLP PROTAC Degrader

Velez, J., Han, Y., Yim, H., Yang, P., Deng, Z., Park, K., Kabir, M., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02394 · Cited by 21 · see citing works

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022

Rekha, T. N., & Shin, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065190 · Cited by 20 · see citing works

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality

Zhou, Y., Xu, S., López‐Carrobles, N., Ding, D., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0019 · Cited by 19 · see citing works

Overview of PRMT1 modulators: Inhibitors and degraders

Wu, J., Li, D., & Wang, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116887 · Cited by 19 · see citing works

Coming of Age: Targeting Cyclin K in Cancers

Xiao, Y., & Dong, J. (2023) · Cells · doi:10.3390/cells12162044 · Cited by 18 · see citing works

Machine learning in targeted protein degradation drug design: a technical review of PROTACs and molecular glues

Lin, C., Shiau, Y., & Lin, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104563 · Cited by 17 · see citing works

Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation

Deng, Z.-J., Catlett, J. L., Lee, Y., Wu, Q., Xu, Z., Xie, L., Chen, X., Xiong, Y., Kaniskan, H., & Jin, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00295 · Cited by 16 · see citing works

Ferritin-Conjugated PROTAC Strategy for ERCC1/XPF Degradation and Platinum Sensitization in Resistant Tumors

Wang, S., Zhao, R., Wang, S., Gui, Z., Hou, M., Yan, X., & Jiang, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01071 · Cited by 16 · see citing works

Lysosome and related protein degradation technologies

Zheng, H., Li, G., Min, J., Xu, X., & Huang, W. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103767 · Cited by 16 · see citing works

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Zhang, R., Xie, S., Ran, J., & Li, T. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31255 · Cited by 15 · see citing works

Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo

Ju, Y., Song, H., He, Y., Lo, Y., Fan, Z., & Lu, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01022 · Cited by 14 · see citing works

Discovery of HyT‐Based Degraders of CDK9‐Cyclin T1 Complex

Lin, R., Yang, J., Liu, T., Wang, M., Ke, C., Luo, C., Lin, J. H., Li, J., & Lin, H. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300769 · Cited by 15 · see citing works

The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease

Zhang, Y. L., Yang, J., Min, J., Huang, S. H., Li, Y., & Liu, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06255-2 · Cited by 13 · see citing works

EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy

Wang, D., Liu, Y., Chen, Y., Dai, C., Hu, W., Han, J., Li, Z., Yin, F., Zhang, Y., & Chen, S. (2025) · Advanced Science · doi:10.1002/advs.202510197 · Cited by 13 · see citing works

Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader

Kabir, M., Qin, L., Luo, K., Xiong, Y., Sidi, R. A., Park, K., & Jin, J. J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00538 · Cited by 13 · see citing works

Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer

Feng, Z., Wang, S., Yu, S. J., Qu, C., Chu, B., & Qian, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116780 · Cited by 13 · see citing works

Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function

Jin, Y., Qi, X., Yu, X., Cheng, X., Chen, B., Wu, M., Zhang, J., Yin, H., Lu, Y., Zhou, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.01.021 · Cited by 13 · see citing works

Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates

Cheng, B., Ding, Z., Hong, Y., Wang, Y., Zhou, Y., Chen, J., Peng, X., & Zeng, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117347 · Cited by 14 · see citing works

Targeting autophagy drug discovery: Targets, indications and development trends

Jiang, M., Wu, W., Xiong, Z., Ye, Z., Ye, Z., & Wu, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116117 · Cited by 13 · see citing works

Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer

Wu, S., Xu, J., Ma, Y., Liang, G., Wang, J., & Sun, T. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241282499 · Cited by 12 · see citing works

Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities

Li, S., Pan, W., Tao, C., Hu, Z., Cheng, B., Chen, J., & Peng, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02106 · Cited by 11 · see citing works

ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics

Sridaran, D., & Mahajan, N. P. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.11.006 · Cited by 11 · see citing works

Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6

Zhao, S., Luo, J., Xu, P., Zeng, J., Yan, G., Yu, F., Qin, L., Zhang, C., Li, P., Cai, M., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142667 · Cited by 11 · see citing works

Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer

Liang, J., Wang, D., Wu, Y., Shi, J., Xie, B., Xiao, R., Ni, J., Wang, C., Dong, C., Shu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00425 · Cited by 11 · see citing works

Bifunctional robots inducing targeted protein degradation

Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11 · see citing works

Discovery of small molecule degraders for modulating cell cycle

Wang, L., Yang, Z., Li, G., Liu, Y., Ai, C., & Rao, Y. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1027-5 · Cited by 10 · see citing works

Natural Compound‐Rhein and PROTACs Unleash Potent VEGFR‐2 Degraders

Zhang, Z., Xu, M., Shi, R., He, X., Wang, Y., Shao, Y., Huang, C., Zhang, F., Zhang, P., & Liu, J. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400753 · Cited by 10 · see citing works

Targeted degradation of LRG1 to attenuate renal fibrosis

Fan, L., Qi, Y., Yang, X., Xu, Y., Zhang, Y., Wang, L., Zhu, A., Zhang, L., Song, J., Du, S., et al. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100941 · Cited by 10 · see citing works

Non-coding RNA and drug resistance in head and neck cancer

Zhang, Y., Peng, Y., Lin, B., Yang, S., Deng, F., Yang, X., Li, A., Xia, W., Gao, C., Lei, S., et al. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.59 · Cited by 10 · see citing works

Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability

Wang, Z., Yue, S., Chen, X., Li, J., Zhu, P., Chen, H., Qiu, F., Xie, D., Liang, Y., Li, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01228 · Cited by 11 · see citing works

In situ construction of intracellular supramolecular assemblies as an alternative strategy for protein degradation

Hu, X., Yao, Q., Wu, X., Chen, J., Zhang, R., Zhao, Y., & Gao, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-61175-5 · Cited by 10 · see citing works

Targeting the cell-cycle machinery for cancer therapy

Peng, Y., Liu, J., Inuzuka, H., Liu, J., & Wei, W. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.08.008 · Cited by 10 · see citing works

Targeted protein degradation of Wnt/β-catenin signaling pathway: an effective strategy for cancer therapy

Mao, S., Zhang, X., Zhao, Y., Li, X., Wang, Z., Zhou, P., Wang, Z., Zhang, X., Hu, X., Huang, G., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07333-1 · Cited by 9 · see citing works

Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor

Pu, C., Liu, Y., Fan, H., Fan, H., Liu, J., Liu, J., & Guo, Y. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117970 · Cited by 8 · see citing works

MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell

Yuan, Z., Guo, M., Zhang, Y., Deng, Y., Sun, B., Hou, Y., Wang, X., Jin, X. J., Liu, Y., Shi, B., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02392-1 · Cited by 9 · see citing works

DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation

Zheng, R., Prasad, A., Satyabola, D., Xu, Y., Roy, S., Yan, Y., Šulc, P., & Yan, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04918 · Cited by 8 · see citing works

FDA-approved kinase inhibitors in PROTAC design, development and synthesis

Kossakowski, K., Cherniienko, A., Zaprutko, L., & Pawełczyk, A. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2542357 · Cited by 8 · see citing works

A Multi-Split-and-Mix Platform for a Variety of Targeted Protein Degradation

Wang, Y., Luo, Q., Xing, Y., Wang, R. Y., Yang, F., Cao, W., Li, Z., & Yin, F. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00444 · Cited by 7 · see citing works

Mechanisms that matter: unbiased cellular screening for degraders

Burston, H. E., Rosethorne, E. M., Cavallo, F., Jordan, A. M., Baruah, P. S., Swift, D., & Hjerpe, R. (2025) · npj Drug Discovery. · doi:10.1038/s44386-025-00028-z · Cited by 7 · see citing works

Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy

Zheng, M., Zhang, X., Chen, W., Xia, F., Yang, H., Yuan, K., & Yang, P. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0259 · Cited by 7 · see citing works

Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs

Zhang, S.-H., Zeng, N., Xu, J., Liu, C., Xu, M., Sun, J., An, Y., Zhong, X., Miao, L.-T., Wang, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117584 · Cited by 7 · see citing works

DNA polymerase theta in cancer therapy: mechanism of action and modulator development

Wu, J., Xu, Y., & Xiao, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117513 · Cited by 6 · see citing works

Harnessing Multiplexed Proteolysis-Targeting Chimera for Comprehensive Influenza A Virus Targeting

Liu, Y., Yu, C., Li, J., Zhang, M., Feng, S., Tian, Z., Wang, Z., Pang, D., & Liu, S. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c09384 · Cited by 6 · see citing works

Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance

Sarwan, D. N., Khedekar, P. B., Bhole, R. P., & Chikhale, R. V. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00136-w · Cited by 5 · see citing works

Opportunities and challenges of PROTAC in the treatment of protein-driven diseases

Zhou, Z., Liu, P., Li, Y., Liu, X., & Li, J. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103234 · Cited by 5 · see citing works

Engineering Polymeric Nano-PROTAC for Targeted Protein Degradation and Cancer Therapy

Saeed, M., Amina, Z., Xu, Z., & Yu, H. (2026) · Polymer science & technology. · doi:10.1021/polymscitech.5c00122 · Cited by 5 · see citing works

Functionalized Photoimmune Hydrogel Microspheres for Inside‐Out Eradication of Osteosarcoma via a PD‐L1 PROTAC Strategy

Luo, H., Ma, J., Yang, H., Hu, H., Xu, Z., Jin, L., Chen, J., Qian, C., Ju, J., Zhang, Y., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503988 · Cited by 3 · see citing works

Diversified design strategies for small-molecule PROTACs: How do we select?

Chen, Q., & Liang, J.-H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118593 · Cited by 3 · see citing works

Bridged PROTAC, DNA-based PROTAC and hydrophobic tag technologies for targeted protein degradation

Gao, P., Zhong, Y., Luo, K., & Jin, J. J. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115819 · Cited by 3 · see citing works

NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigms

Qian, J., Duan, H., Zheng, Q., Yang, Y., Huang, X., Shi, B., & Zhang, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115821 · Cited by 3 · see citing works

PROTACs for central nervous system disorders: challenges and opportunities

Zheng, N., Shao, J., Xiong, B., Wei, Y., Wang, X., Zhou, Y., Song, Z., Zhang, A., Xu, C., Zhao, Q., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118703 · Cited by 3 · see citing works

All-component-active metal–organic frameworks for tailored chemoradiotherapy of self-defensive tumors

Xu, X., Yang, Z., Bao, S., Xu, Z., Liu, T., Wu, L., & Lei, J. (2025) · Chemical Science · doi:10.1039/d5sc02482j · Cited by 3 · see citing works

Discovery of Highly Potent and Orally Available CCNK Molecular Glue Degraders as Broad-Spectrum Antitumor Agents

Liu, Y., Yang, Z., Liao, Z., Chen, S., Qin, Z., Liang, Z., Chen, L., Bao, C., Wei, M., Zhang, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01681 · Cited by 2 · see citing works

Decoding microbial carcinogenic strategies: ubiquitination and SUMO modification

Liu, Y., Zeng, X., Lyu, Z., & Huang, D. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1720153 · Cited by 2 · see citing works

Emerging methods to improve PROTAC transport across cell membrane

Veisi, F., & Ataei, F. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.173175 · Cited by 2 · see citing works

Targeted Protein Degradation Strategies for Lung Cancers: Focusing on Epidermal Growth Factor Receptor

Hou, M., Li, M., Zhao, J., Gong, Y., Rong, J., Feng, Z., Sun, H., & Zeng, J. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202503126 · Cited by 2 · see citing works

Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies

An, X., Xie, J., Wang, W., Long, T., Liang, Q., & Hou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105186 · Cited by 2 · see citing works

Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.

Tu, Y.-T., Cai, X., Tao, Z.-F., Zhang, R., Li, X., Chen, B.-J., Zhang, H.-L., Hu, X.-B., Ke, J., Chen, X., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02925-2 · Cited by 3 · see citing works

Discovery of a First‐in‐Class Murine Double Minute 2‐Recruiting Positive Transcription Elongation Factor B PROTAC Degrader With Selective Antitumor Activity

Guan, X., Xie, L., Guo, H., Ma, L., Zhou, J., Luo, L., Yang, H., Wu, Y., Liu, J., Wang, Y., et al. (2026) · MedComm · doi:10.1002/mco2.70723 · Cited by 2 · see citing works

Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on “undruggable” targets

Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3 · see citing works

Crosstalk between lactylation and other post-translational modifications in health and diseases

Qi, W., Su, J., He, X., Yang, F., Li, Q., & Li, B. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00500-w · Cited by 2 · see citing works

An EZH2–SREBP2 axis promotes cholesterol biosynthesis and represents a noncanonical vulnerability in tumorigenesis

Kim, A., Pan, B., Yu, X., Gao, X., Khudaverdyan, N., Taherian, F., Xu, C., Zhong, H., Xiong, Y., Kanıskan, H. Ü., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-02048-x · Cited by 2 · see citing works

Sirtuin 3 as a promising target in disease therapy: Model action and drug discovery

Yu, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117929 · Cited by 2 · see citing works

Abstract 394: Bridged proteolysis targeting chimera (PROTAC) enables degradation of the cyclin D undruggable protein

Zhong, Y., Xiong, Y., Yim, H., Yang, X., Park, K., Xie, L., Poulikakos, P. I., Chen, X., Liu, J., & Jin, J. J. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-394

Bridged PROTAC, DNA-based PROTAC and hydrophobic tag technologies for targeted protein degradation

Gao, P., Zhong, Y., Luo, K., & Jin, J. J. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115819 · Cited by 3 · see citing works

Discovery of proteolysis-targeting chimera targeting undruggable proteins using a covalent ligand screening approach

Lee, H., Lee, J. Y., Jang, H., Cho, H. Y., Kang, M., Bae, S. H., Kim, E., Kim, E., Jang, J., Kim, J. Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115929 · Cited by 7 · see citing works

New Drug Discovery Approaches to target undruggable oncogenic targets

Sánchez‐Arfelis, A. (2025) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)

Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy

Zhang, X., Song, Z., Zhang, X., Zou, J., Yu, G., Chen, X. S., & Wang, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202507702 · Cited by 4 · see citing works